{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:12:47Z","timestamp":1790183567907,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01020-z","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:10:59Z","timestamp":1765203059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-2779","authenticated-orcid":false,"given":"Prasanna Srinivasan","family":"Ramalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3554-1750","authenticated-orcid":false,"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-3594","authenticated-orcid":false,"given":"Gayathri","family":"Chellasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-9874","authenticated-orcid":false,"given":"Sujatha","family":"Elangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3376-0847","authenticated-orcid":false,"given":"Divya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0651-8259","authenticated-orcid":false,"given":"Premkumar","family":"T","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-5320","authenticated-orcid":false,"given":"Rudra Awdhesh Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1576-5324","authenticated-orcid":false,"given":"Gothandam","family":"Kodiveri Muthukaliannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-1417","authenticated-orcid":false,"given":"Tajamul","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0120-0309","authenticated-orcid":false,"given":"Salman","family":"Alrokayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6259-6941","authenticated-orcid":false,"given":"Purushothaman","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1814-2819","authenticated-orcid":false,"given":"Janaki Ramaiah","family":"Mekala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-8834","authenticated-orcid":false,"given":"Sivakumar","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. Cancer J Clin. 2025;75:10\u201345.","journal-title":"Cancer J Clin"},{"key":"1020_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41392-025-02129-7","volume":"10","author":"R Nussinov","year":"2025","unstructured":"Nussinov R, Yavuz BR, Jang H. Molecular principles underlying aggressive cancers. Signal Transduct Target Therapy. 2025;10:42.","journal-title":"Signal Transduct Target Therapy"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","volume":"23","author":"M Araghi","year":"2023","unstructured":"Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23:162.","journal-title":"Cancer Cell Int"},{"key":"1020_CR4","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0594","author":"I Kaushik","year":"2025","unstructured":"Kaushik I, Rajan R, Gaikwad S, Eltokhy MA, Srivastava SK. Moxidectin unravels the role of Hippo-YAP pathway in maintaining immunity of glioblastoma multiforme. Mol Cancer Ther. 2025. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0594.","journal-title":"Mol Cancer Ther"},{"key":"1020_CR5","first-page":"141","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer drug resistance (Alhambra. Calif). 2019;2:141\u201360.","journal-title":"Calif)"},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12935-024-03558-0","volume":"24","author":"BA Mengistu","year":"2024","unstructured":"Mengistu BA, Tsegaw T, Demessie Y, Getnet K, Bitew AB, Kinde MZ, et al. Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy. Cancer Cell Int. 2024;24:406.","journal-title":"Cancer Cell Int"},{"key":"1020_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/minf.201400070","volume":"34","author":"A Kumar","year":"2015","unstructured":"Kumar A, Shanthi V, Ramanathan K. Computational investigation and experimental validation of Crizotinib resistance conferred by C1156Y mutant anaplastic lymphoma kinase. Mol Inf. 2015;34:105\u201314.","journal-title":"Mol Inf"},{"key":"1020_CR8","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.1080\/14786419.2020.1799361","volume":"35","author":"SS K","year":"2021","unstructured":"K SS. Exploring natural compounds for the management of non-small cell lung cancer. Nat Prod Res. 2021;35:5879\u201382.","journal-title":"Nat Prod Res"},{"key":"1020_CR9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/cimb45030137","volume":"45","author":"PS Ramalingam","year":"2023","unstructured":"Ramalingam PS, Balakrishnan P, Rajendran S, Jothi A, Ramalingam R, Arumugam S. Identification of dietary bioflavonoids as potential inhibitors against KRAS G12D Mutant-Novel insights from Computer-Aided drug discovery. Curr Issues Mol Biol. 2023;45:2136\u201356.","journal-title":"Curr Issues Mol Biol"},{"key":"1020_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s13205-023-03767-w","volume":"13","author":"PS Ramalingam","year":"2023","unstructured":"Ramalingam PS, Arumugam S. Computational design and validation of effective SiRNAs to silence oncogenic KRAS. 3 Biotech. 2023;13:350.","journal-title":"3 Biotech"},{"key":"1020_CR11","first-page":"283","volume-title":"Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS","author":"PS Ramalingam","year":"2023","unstructured":"Ramalingam PS, Arumugam S. Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS. Volume 40. London, England: Medical oncology (Northwood; 2023. p. 283."},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"1107128","DOI":"10.3389\/fmed.2023.1107128","volume":"10","author":"PS Ramalingam","year":"2023","unstructured":"Ramalingam PS, Priyadharshini A, Emerson IA, Arumugam S. Potential biomarkers uncovered by bioinformatics analysis in Sotorasib resistant-pancreatic ductal adenocarcinoma. Front Med. 2023;10:1107128.","journal-title":"Front Med"},{"key":"1020_CR13","doi-asserted-by":"crossref","unstructured":"Huang B, An H, Chu J, Ke S, Ke J, Qiu Y, et al. Glucose-responsive and analgesic gel for diabetic subcutaneous abscess treatment by simultaneously boosting photodynamic therapy and relieving hypoxia. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2025;e02830.","DOI":"10.1002\/advs.202502830"},{"key":"1020_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin W-L. Drug repurposing for cancer therapy. Signal Transduct Target Therapy. 2024;9:92.","journal-title":"Signal Transduct Target Therapy"},{"key":"1020_CR15","doi-asserted-by":"crossref","unstructured":"James N, Shanthi V, Ramanathan K. Tackling lung cancer drug resistance using integrated drug-repurposing strategy. In: Silico Drug Design: Repurposing Techniques and Methodologies. 2019. p. 549\u201375.","DOI":"10.1016\/B978-0-12-816125-8.00018-3"},{"key":"1020_CR16","doi-asserted-by":"crossref","unstructured":"Feng C, Wang Y, Xu J, Zheng Y, Zhou W, Wang Y, et al. Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect. Pharmaceutics. 2024;16.","DOI":"10.3390\/pharmaceutics16121582"},{"key":"1020_CR17","doi-asserted-by":"crossref","unstructured":"Al Khzem AH, Gomaa MS, Alturki MS, Tawfeeq N, Sarafroz M, Alonaizi SM, et al. Drug repurposing for cancer treatment: a comprehensive review. Int J Mol Sci. 2024;25.","DOI":"10.20944\/preprints202410.2321.v1"},{"key":"1020_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bmb\/ldaa045","volume":"137","author":"CH Schein","year":"2021","unstructured":"Schein CH. Repurposing approved drugs for cancer therapy. Br Med Bull. 2021;137:13\u201327.","journal-title":"Br Med Bull"},{"key":"1020_CR19","doi-asserted-by":"publisher","first-page":"800995","DOI":"10.3389\/fendo.2022.800995","volume":"13","author":"B Zhu","year":"2022","unstructured":"Zhu B, Qu S. The relationship between diabetes mellitus and cancers and its underlying mechanisms. Front Endocrinol. 2022;13:800995.","journal-title":"Front Endocrinol"},{"key":"1020_CR20","doi-asserted-by":"crossref","unstructured":"Pliszka M, Szablewski L. Associations between diabetes mellitus and selected cancers. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25137476"},{"key":"1020_CR21","doi-asserted-by":"publisher","first-page":"1263650","DOI":"10.3389\/fendo.2023.1263650","volume":"14","author":"Y Hou","year":"2023","unstructured":"Hou Y, Xiang J, Wang B, Duan S, Song R, Zhou W, et al. Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes mellitus. Front Endocrinol. 2023;14:1263650.","journal-title":"Front Endocrinol"},{"key":"1020_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1186\/s12885-023-11344-w","volume":"23","author":"F Amri","year":"2023","unstructured":"Amri F, Belkhayat C, Yeznasni A, Koulali H, Jabi R, Zazour A, et al. Association between pancreatic cancer and diabetes: insights from a retrospective cohort study. BMC Cancer. 2023;23:856.","journal-title":"BMC Cancer"},{"key":"1020_CR23","doi-asserted-by":"crossref","unstructured":"Li R, Luo P, Guo Y, He Y, Wang C. Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis. Exp Opin Drug Saf. 2024;1\u20135.","DOI":"10.1080\/14740338.2024.2396387"},{"key":"1020_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fendo.2019.00080","volume":"10","author":"CF Deacon","year":"2019","unstructured":"Deacon CF. Physiology and Pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. 2019;10:80.","journal-title":"Front Endocrinol"},{"key":"1020_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Therapy. 2024;9:234.","journal-title":"Signal Transduct Target Therapy"},{"key":"1020_CR26","doi-asserted-by":"publisher","first-page":"149897","DOI":"10.1016\/j.bbrc.2024.149897","volume":"711","author":"S Tsuji","year":"2024","unstructured":"Tsuji S, Kudo U, Hatakeyama R, Shoda K, Nakamura S, Shimazawa M. Linagliptin decreased the tumor progression on glioblastoma model. Biochem Biophys Res Commun. 2024;711:149897.","journal-title":"Biochem Biophys Res Commun"},{"key":"1020_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fphar.2020.00187","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Li Y, Li D, Li K, Quan Z, Wang Z, et al. Repositioning of hypoglycemic drug linagliptin for cancer treatment. Front Pharmacol. 2020;11:187.","journal-title":"Front Pharmacol"},{"key":"1020_CR28","doi-asserted-by":"crossref","unstructured":"Busek P, Duke-Cohan JS, Sedo A. Does DPP-IV Inhibition offer new avenues for therapeutic intervention in malignant disease? Cancers. 2022;14.","DOI":"10.3390\/cancers14092072"},{"key":"1020_CR29","doi-asserted-by":"publisher","first-page":"9436238","DOI":"10.1155\/2024\/9436238","volume":"2024","author":"PS Ramalingam","year":"2024","unstructured":"Ramalingam PS, Raj DBTG, Subramanian M, Arumugam S. ML-Based screening of MiRNA inhibitors and intervention of lncRNA\/miRNA\/mRNA axis in oncogenic KRAS-Associated colorectal cancer. Adv Public Health. 2024;2024:9436238.","journal-title":"Adv Public Health"},{"key":"1020_CR30","doi-asserted-by":"publisher","first-page":"109876","DOI":"10.1016\/j.cbi.2022.109876","volume":"357","author":"JR Mekala","year":"2022","unstructured":"Mekala JR, Ramalingam PS, Mathavan S, Yamajala RBRD, Moparthi NR, Kurappalli RK, et al. Synthesis, in vitro and structural aspects of cap substituted suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in glioblastoma cancer cells via HDAC\/microRNA regulation. Chemico-Biol Interact. 2022;357:109876.","journal-title":"Chemico-Biol Interact"},{"key":"1020_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40360-018-0284-4","volume":"20","author":"X Wang","year":"2019","unstructured":"Wang X, Decker CC, Zechner L, Krstin S, Wink M. In vitro wound healing of tumor cells: Inhibition of cell migration by selected cytotoxic alkaloids. BMC Pharmacol Toxicol. 2019;20:4.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1020_CR32","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1038\/s41598-023-32442-6","volume":"13","author":"D Nakamura","year":"2023","unstructured":"Nakamura D. The evaluation of tumorigenicity and characterization of colonies in a soft agar colony formation assay using polymerase chain reaction. Sci Rep. 2023;13:5405.","journal-title":"Sci Rep"},{"key":"1020_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-60761-411-1_4","volume":"594","author":"E Eruslanov","year":"2010","unstructured":"Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biology (Clifton NJ). 2010;594:57\u201372.","journal-title":"Methods Mol Biology (Clifton NJ)"},{"key":"1020_CR34","doi-asserted-by":"publisher","first-page":"104225","DOI":"10.1016\/j.jff.2020.104225","volume":"75","author":"CC Chu","year":"2020","unstructured":"Chu CC, Chen SY, Chyau CC, Wu YC, Chu HL, Duh P, Der. Anticancer activity and mediation of apoptosis in hepatoma carcinoma cells induced by Djulis and its bioactive compounds. J Funct Foods. 2020;75:104225.","journal-title":"J Funct Foods"},{"key":"1020_CR35","doi-asserted-by":"crossref","unstructured":"Wu I-T, Kuo C-Y, Su C-H, Lan Y-H, Hung C-C. Pinostrobin and tectochrysin conquer multidrug-resistant cancer cells via inhibiting P-Glycoprotein ATPase. Pharmaceuticals (Basel, Switzerland). 2023;16.","DOI":"10.3390\/ph16020205"},{"key":"1020_CR36","doi-asserted-by":"publisher","first-page":"17216","DOI":"10.18632\/oncotarget.15303","volume":"8","author":"SK Singh","year":"2017","unstructured":"Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53\/p21WAF1\/CIP1 and p27KIP1 pathway. Oncotarget. 2017;8:17216\u201328.","journal-title":"Oncotarget"},{"key":"1020_CR37","doi-asserted-by":"publisher","first-page":"1078642","DOI":"10.3389\/fnut.2022.1078642","volume":"9","author":"M Suhail","year":"2022","unstructured":"Suhail M, Rehan M, Tarique M, Tabrez S, Husain A, Zughaibi TA. Targeting a transcription factor NF-\u03baB by green tea catechins using in Silico and in vitro studies in pancreatic cancer. Front Nutr. 2022;9:1078642.","journal-title":"Front Nutr"},{"key":"1020_CR38","doi-asserted-by":"publisher","first-page":"baq020","DOI":"10.1093\/database\/baq020","volume":"2010","author":"M Safran","year":"2010","unstructured":"Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al. GeneCards version 3: the human gene integrator. Database: J Biol Databases Curation. 2010;2010:baq020.","journal-title":"Database: J Biol Databases Curation"},{"key":"1020_CR39","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357\u201364.","journal-title":"Nucleic Acids Res"},{"key":"1020_CR40","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638\u201346.","journal-title":"Nucleic Acids Res"},{"key":"1020_CR41","first-page":"291","volume":"696","author":"M Kohl","year":"2011","unstructured":"Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. (Clifton NJ). 2011;696:291\u2013303. Methods in molecular biology.","journal-title":"(Clifton NJ)"},{"key":"1020_CR42","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1020_CR43","first-page":"2628","volume":"36","author":"SX Ge","year":"2020","unstructured":"Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinf (Oxford England). 2020;36:2628\u20139.","journal-title":"Bioinf (Oxford England)"},{"key":"1020_CR44","doi-asserted-by":"crossref","unstructured":"Yan Q, Li X, Chen Y, Li L, Hu X. Efficacy of supportive care interventions for improving posttraumatic stress symptoms and resilience in family caregivers of cancer-affected children: a meta-analysis of randomized controlled trials. Worldviews Evid Based Nurs. 2025;22:e12764.","DOI":"10.1111\/wvn.12764"},{"key":"1020_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12668-025-01873-y","volume":"15","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Prajapati BG, Gandhi SM, Sharma M, Kapoor DU, Elossaily GM, et al. Overcoming obstacles: the role of lipid nanocarriers in therapeutic approaches for pancreatic cancer. BioNanoScience. 2025;15:1\u201317.","journal-title":"BioNanoScience"},{"key":"1020_CR46","doi-asserted-by":"publisher","first-page":"156001","DOI":"10.1016\/j.prp.2025.156001","volume":"270","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Eltaib L, Rana AJ, Maqbool M, Ashique S, Alanazi MN, et al. Exploiting E3 ligases for lung cancer therapy: the promise of DCAF-PROTACs. Pathol - Res Pract. 2025;270:156001.","journal-title":"Pathol - Res Pract"},{"key":"1020_CR47","doi-asserted-by":"publisher","first-page":"116492","DOI":"10.1016\/j.bcp.2024.116492","volume":"229","author":"M Espona-Fiedler","year":"2024","unstructured":"Espona-Fiedler M, Patthey C, Lindblad S, Sarr\u00f3 I, \u00d6hlund D. Overcoming therapy resistance in pancreatic cancer: new insights and future directions. Biochem Pharmacol. 2024;229:116492.","journal-title":"Biochem Pharmacol"},{"key":"1020_CR48","doi-asserted-by":"crossref","unstructured":"Kumar L, Kumar S, Sandeep K, Patel SKS. Therapeutic approaches in pancreatic cancer: recent updates. Biomedicines. 2023;11.","DOI":"10.3390\/biomedicines11061611"},{"key":"1020_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi A-A. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17:40.","journal-title":"J Hematol Oncol"},{"key":"1020_CR50","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12:173\u201381.","journal-title":"World J Gastrointest Oncol"},{"key":"1020_CR51","doi-asserted-by":"publisher","first-page":"103470","DOI":"10.1016\/j.cis.2025.103470","volume":"340","author":"L Guo","year":"2025","unstructured":"Guo L, Fu Z, Li H, Wei R, Guo J, Wang H, et al. Smart hydrogel: A new platform for cancer therapy. Adv Colloid Interface Sci. 2025;340:103470.","journal-title":"Adv Colloid Interface Sci"},{"key":"1020_CR52","doi-asserted-by":"publisher","first-page":"13761","DOI":"10.1007\/s11356-020-11435-2","volume":"28","author":"VK Chaturvedi","year":"2021","unstructured":"Chaturvedi VK, Yadav N, Rai NK, Bohara RA, Rai SN, Aleya L, et al. Two birds with one stone: oyster mushroom mediated bimetallic Au-Pt nanoparticles for agro-waste management and anticancer activity. Environ Sci Pollut Res Int. 2021;28:13761\u201375.","journal-title":"Environ Sci Pollut Res Int"},{"key":"1020_CR53","doi-asserted-by":"publisher","first-page":"10296","DOI":"10.1039\/D3NJ00182B","volume":"47","author":"BR Swain","year":"2023","unstructured":"Swain BR, Jena SR, Beriha SK, Mahanta CS, Jena BB, Prasanth T, et al. Synthesis and anticancer properties of dendritic glycoconjugates containing multiple o-carborane clusters. New J Chem. 2023;47:10296\u2013308.","journal-title":"New J Chem"},{"key":"1020_CR54","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1039\/D4CC00129J","volume":"60","author":"B Lala","year":"2024","unstructured":"Lala B, Chaudhuri R, Prasanth T, Burkhart I, Schwalbe H, Dash J. Guanosine-based hydrogel as a supramolecular scaffold for template-assisted macrocyclization. Chem Commun. 2024;60:3433\u20136.","journal-title":"Chem Commun"},{"key":"1020_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/bs.acr.2021.07.004","volume":"153","author":"RA Burge","year":"2022","unstructured":"Burge RA, Hobbs GA. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations. Adv Cancer Res. 2022;153:29\u201361.","journal-title":"Adv Cancer Res"},{"key":"1020_CR56","doi-asserted-by":"publisher","first-page":"102309","DOI":"10.1016\/j.ctrv.2021.102309","volume":"101","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou S-HI. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev. 2021;101:102309.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1020_CR57","first-page":"1","volume":"10","author":"T Kos","year":"2025","unstructured":"Kos T, Saur D. Breaking down KRAS: small-molecule degraders for cancer therapy. Signal Transduct Target Therapy 2025. 2025;10(1):86:1\u20133.","journal-title":"Signal Transduct Target Therapy 2025"},{"key":"1020_CR58","doi-asserted-by":"publisher","first-page":"148659","DOI":"10.1016\/j.gene.2024.148659","volume":"927","author":"A Niazmand","year":"2024","unstructured":"Niazmand A, Nedaeinia R, Vatandoost N, Jafarpour S, Safabakhsh S, Kolahdouz M, et al. The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: A systematic review. Gene. 2024;927:148659.","journal-title":"Gene"},{"key":"1020_CR59","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/ijc.20091","volume":"109","author":"UV Wesley","year":"2004","unstructured":"Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human Non small cell lung carcinoma cells. Int J Cancer. 2004;109:855\u201366.","journal-title":"Int J Cancer"},{"key":"1020_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3892\/ol.2015.3151","volume":"10","author":"M Zhang","year":"2015","unstructured":"Zhang M, Xu L, Wang X, Sun B, Ding J. Expression levels of seprase\/FAP\u03b1 and DPPIV\/CD26 in epithelial ovarian carcinoma. Oncol Lett. 2015;10:34\u201342.","journal-title":"Oncol Lett"},{"key":"1020_CR61","doi-asserted-by":"crossref","unstructured":"Ng L, Foo DC-C, Wong CK-H, Man AT-K, Lo OS-H. Law W-L. Repurposing DPP-4 inhibitors for colorectal cancer: a retrospective and single center study. Cancers. 2021;13.","DOI":"10.3390\/cancers13143588"},{"key":"1020_CR62","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1007\/s12094-023-03187-5","volume":"25","author":"B Zuo","year":"2023","unstructured":"Zuo B, Li T, Liu X, Wang S, Cheng J, Liu X, et al. Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer. Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2023;25:3188\u2013202.","journal-title":"Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"key":"1020_CR63","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1111\/bph.13274","volume":"172","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Kim JY, Lim S-C, Kim G, Yun HJ, Choi HS. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression. Br J Pharmacol. 2015;172:5096\u2013109.","journal-title":"Br J Pharmacol"},{"key":"1020_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.dsx.2018.08.012","volume":"13","author":"AG Almagthali","year":"2019","unstructured":"Almagthali AG, Alkhaldi EH, Alzahrani AS, Alghamdi AK, Alghamdi WY, Kabel AM. Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer. Diabetes Metabolic Syndrome. 2019;13:36\u20139.","journal-title":"Diabetes Metabolic Syndrome"},{"key":"1020_CR65","doi-asserted-by":"publisher","first-page":"e22220","DOI":"10.1002\/jbt.22220","volume":"32","author":"W Jiang","year":"2018","unstructured":"Jiang W, Wen D, Cheng Z, Yang Y, Zheng G, Yin F. Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-\u03baB activation and inflammatory cytokines. J Biochem Mol Toxicol. 2018;32:e22220.","journal-title":"J Biochem Mol Toxicol"},{"key":"1020_CR66","doi-asserted-by":"publisher","first-page":"101928","DOI":"10.1016\/j.xcrm.2025.101928","volume":"6","author":"X Shen","year":"2025","unstructured":"Shen X, Chen Y, Tang Y, Lu P, Liu M, Mao T, et al. Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Cell Rep Med. 2025;6:101928.","journal-title":"Cell Rep Med"},{"key":"1020_CR67","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.4314\/ahs.v18i4.51","volume":"18","author":"F Karaku\u015f","year":"2018","unstructured":"Karaku\u015f F, Eyol E, Y\u0131lmaz K, \u00dcn\u00fcvar S. Inhibition of cell proliferation, migration and colony formation of LS174T cells by carbonic anhydrase inhibitor. Afr Health Sci. 2018;18:1303\u201310.","journal-title":"Afr Health Sci"},{"key":"1020_CR68","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41419-024-06939-5","volume":"15","author":"X An","year":"2024","unstructured":"An X, Yu W, Liu J, Tang D, Yang L, Chen X. Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis. 2024;15:556.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1020_CR69","first-page":"6","volume":"93","author":"P Thumpati","year":"2025","unstructured":"Thumpati P, Rai SN, Prajapati C, Ramakrishna K, Singh SK. Targeting c-MYC G-Quadruplexes for cancer treatment with small molecules. Scientia Pharm 2025. 2025;93(6):93:6.","journal-title":"Scientia Pharm 2025"},{"key":"1020_CR70","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.biochi.2020.04.009","volume":"174","author":"DD Zhdanov","year":"2020","unstructured":"Zhdanov DD, Plyasova AA, Pokrovsky VS, Pokrovskaya MV, Alexandrova SS, Gladilina YA, et al. Inhibition of nuclease activity by a splice-switching oligonucleotide targeting deoxyribonuclease 1 mRNA prevents apoptosis progression and prolong viability of normal human CD4\u2009+\u2009T-lymphocytes. Biochimie. 2020;174:34\u201343.","journal-title":"Biochimie"},{"key":"1020_CR71","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.bcp.2008.09.009","volume":"76","author":"X Qian","year":"2008","unstructured":"Qian X, Li J, Ding J, Wang Z, Duan L, Hu G. Glibenclamide exerts an antitumor activity through reactive oxygen species\u2013c-jun NH(2)-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol. 2008;76:1705\u201315.","journal-title":"Biochem Pharmacol"},{"key":"1020_CR72","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati V, Mahapatra DK, Bharti SK. PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and Pharmacological perspectives. Eur J Med Chem. 2016;109:314\u201341.","journal-title":"Eur J Med Chem"},{"key":"1020_CR73","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbrc.2015.07.118","volume":"465","author":"G Cheng","year":"2015","unstructured":"Cheng G, Lanza-Jacoby S. Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: role of NOX4. Biochem Biophys Res Commun. 2015;465:41\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"1020_CR74","doi-asserted-by":"publisher","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","volume":"12","author":"S Qian","year":"2022","unstructured":"Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022;12:985363.","journal-title":"Front Oncol"},{"issue":"1","key":"1020_CR75","first-page":"1","volume":"25","author":"M Saddam","year":"2024","unstructured":"Saddam M, Paul SK, Habib MA, Fahim MA, Mimi A, Islam S, et al. Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context. Egypt J Med Hum Genet 2024. 2024;25(1):25:1\u201328.","journal-title":"Egypt J Med Hum Genet 2024"},{"key":"1020_CR76","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s12010-024-05098-9","volume":"197","author":"C Prajapati","year":"2025","unstructured":"Prajapati C, Rai SN, Singh AK, Chopade BA, Singh Y, Singh SK, et al. An update of fungal endophyte diversity and strategies for augmenting therapeutic potential of their potent metabolites: recent advancement. Appl Biochem Biotechnol. 2025;197:2799\u2013866.","journal-title":"Appl Biochem Biotechnol"},{"key":"1020_CR77","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s43556-024-00204-z","volume":"5","author":"Y Dhas","year":"2024","unstructured":"Dhas Y, Biswas N, Jones MRD, Ashili LD. Repurposing metabolic regulators: antidiabetic drugs as anticancer agents. Mol Biomed. 2024;5:40.","journal-title":"Mol Biomed"},{"key":"1020_CR78","doi-asserted-by":"crossref","unstructured":"Mishra D, Mishra A, Rai SN, Vamanu E, Singh MP. Identification of prognostic biomarkers for suppressing tumorigenesis and metastasis of hepatocellular carcinoma through transcriptome analysis. Diagnostics (Basel, Switzerland). 2023;13.","DOI":"10.3390\/diagnostics13050965"},{"key":"1020_CR79","doi-asserted-by":"crossref","unstructured":"Mishra D, Mishra A, Nand Rai S, Vamanu E, Singh MP. Demystifying the role of prognostic biomarkers in breast cancer through integrated transcriptome and pathway enrichment analyses. Diagnostics (Basel, Switzerland). 2023;13.","DOI":"10.3390\/diagnostics13061142"},{"key":"1020_CR80","doi-asserted-by":"crossref","unstructured":"Arif R, Bukhari SA, Mustafa G, Ahmed S, Albeshr MF. Network pharmacology and experimental validation to explore the potential mechanism of Nigella sativa for the treatment of breast cancer. Pharmaceuticals (Basel, Switzerland). 2024;17.","DOI":"10.3390\/ph17050617"},{"key":"1020_CR81","first-page":"1185","volume":"68","author":"S Subburaj","year":"2021","unstructured":"Subburaj S, Nagrale TA, Khan MM, James N, Karuppasamy R, Veerappapillai S. Discovery of anaplastic lymphoma kinase inhibitors from natural product library: A holistic in Silico approach. Biotechnol Appl Chem. 2021;68:1185\u201391.","journal-title":"Biotechnol Appl Chem"},{"key":"1020_CR82","doi-asserted-by":"crossref","unstructured":"Mishra D, Mishra A, Rai SN, Singh SK, Vamanu E, Singh MP. In silico insight to identify potential inhibitors of BUB1B from mushroom bioactive compounds to prevent breast cancer metastasis. Front Biosci (Landmark edition). 2023;28:151.","DOI":"10.31083\/j.fbl2807151"},{"key":"1020_CR83","doi-asserted-by":"crossref","unstructured":"Wy\u017cewski Z, Gregorczyk-Zboroch KP, Mielcarska MB, \u015awitlik W, Niedzielska A. Bid protein: a participant in the apoptotic network with roles in viral infections. Int J Mol Sci. 2025;26.","DOI":"10.3390\/ijms26062385"},{"key":"1020_CR84","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.cdd.4400783","volume":"7","author":"SJ Korsmeyer","year":"2000","unstructured":"Korsmeyer SJ, Wei MC, Saito M, Weilesr S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000;7:1166\u201373.","journal-title":"Cell Death Differ"},{"key":"1020_CR85","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1007\/s11033-019-04772-0","volume":"46","author":"X-W Zhao","year":"2019","unstructured":"Zhao X-W, Zhou J-P, Bi Y-L, Wang J-Y, Yu R, Deng C, et al. The role of MAPK signaling pathway in formation of EMT in oral squamous carcinoma cells induced by TNF-\u03b1. Mol Biol Rep. 2019;46:3149\u201356.","journal-title":"Mol Biol Rep"},{"key":"1020_CR86","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1002\/mco2.659","volume":"5","author":"X Wang","year":"2024","unstructured":"Wang X, Xue X, Pang M, Yu L, Qian J, Li X, et al. Epithelial-mesenchymal plasticity in cancer: signaling pathways and therapeutic targets. MedComm. 2024;5:e659.","journal-title":"MedComm"},{"key":"1020_CR87","doi-asserted-by":"crossref","unstructured":"Duda P, Akula SM, Abrams SL, Steelman LS, Martelli AM, Cocco L, et al. Targeting GSK3 and associated signaling pathways involved in cancer. Cells. 2020;9.","DOI":"10.3390\/cells9051110"},{"key":"1020_CR88","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Therapy. 2021;6:425.","journal-title":"Signal Transduct Target Therapy"},{"key":"1020_CR89","doi-asserted-by":"crossref","unstructured":"Hardwick JM, Soane L. Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5.","DOI":"10.1101\/cshperspect.a008722"},{"key":"1020_CR90","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74\u201388.","journal-title":"Nat Rev Cancer"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01020-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:04:47Z","timestamp":1765206287000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-01020-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01020-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}